SG3 Management’s Acadia Pharmaceuticals ACAD Stock Holding History

SG3 Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64,500	Closed	-$909K	–	278
2022 Q2	$909K	Buy	64,500 +6,463	+11%	+$121K	0.11%	136
2022 Q1	$1.41M	Buy	+58,037	New	+$1.4M	0.04%	386
2021 Q2	–	Sell	-10,000	Closed	-$258K	–	985
2021 Q1	$258K	Buy	+10,000	New	+$440K	0.01%	920
2019 Q3	–	Sell	-7,500	Closed	-$200K	–	319
2019 Q2	$200K	Hold	7,500	–	–	0.02%	286
2019 Q1	$201K	Buy	+7,500	New	+$175K	0.02%	233

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SG3 Management's ACAD Position: Q3 2022 in Review

SG3 Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 64,500 shares — an estimated $909K sold.

SG3 Management first reported a position in ACAD in Q1 2019 and held it in 5 quarters. The position peaked at $1.41M in Q1 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

SG3 Management reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 64,500 Acadia Pharmaceuticals shares in Q3 2022, an estimated $909K.
SG3 Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 5 quarters.
SG3 Management's Acadia Pharmaceuticals position peaked at $1.41M in Q1 2022.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.